ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
The pharmaceutical services firm DPx Holdings has agreed to acquire Gallus BioPharmaceuticals, a contract manufacturer of biologic drugs, for an undisclosed sum. Gallus, owned by the investment firm Ridgemont Equity Partners, has about 370 employees at sites in St. Louis and Princeton, N.J. DPx, which was formed earlier this year through the merger of DSM Fine Chemicals and Patheon, says the purchase will increase employment in its biologics division to 550 and add U.S. locations to biologics facilities it operates in Australia and the Netherlands.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X